Loading organizations...
Loading organizations...
Holobiome: Biotech developing microbiome therapeutics for mental health and metabolic diseases, mapping the gut-brain axis.
Holobiome, based in Boston, Massachusetts, develops microbiome-based therapeutics, including precision probiotics and interventions, for mental health and metabolic diseases by mapping the gut-brain axis and the impact of human gut bacteria on health. The company has raised a total of $10.08 million in funding, including a significant $9 million Seed VC - II round approximately one year ago, and has established early strategic partnerships with Johnson & Johnson Innovation, Janssen, and Amgen. Holobiome leverages a proprietary bacteria dataset and advanced AI/ML to develop its solutions, further expanding its capabilities by acquiring AsiaBiome, Asia's first microbiome startup, in November 2022. Key personnel include CEO and co-founder Philip Strandwitz and Chief Business Officer Jonathan Krive, both instrumental in the company's growth. Holobiome was founded in 2015 by Philip Strandwitz, establishing its presence in the burgeoning biotech sector.
Holobiome has raised $9.0M across 1 funding round.
Holobiome has raised $9.0M in total across 1 funding round.
Holobiome has raised $9.0M in total across 1 funding round.
Holobiome's investors include Joan LaRovere, MD, MSc, MBA.
Holobiome has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 9, 2024 | $9.0M Seed | Joan LaRovere, MD, MSc, MBA |